Allergan’s Mixed R&D News Gives It A Shot In The Eye
This article was originally published in The Pink Sheet Daily
Allergan announced plans to initiate a Phase III clinical trial for its macular degeneration candidate DARPin and FDA approval of a new indication for the eye drug Ozurdex, but FDA also declined to approve Semprana for migraine.
You may also be interested in...
Valeant touted the successes of the B&L acquisition in an effort to prove an Allergan integration would be just as seamless. The increased offer to Allergan came on the heels of Valeant selling its dermatological fillers business to Nestle for $1.4 billion, a move that paves the way for integrating Allergan’s similar portfolio.
Access to branded drugs has remained steady, but there has been less management across brands by commercial payers, according to an analysis of the I&I market access environment by Bernstein.
Biopharmaceuticals President Ruud Dobber talked to Scrip about the launches of Lokelma and roxadustat in kidney disease, building with a high bar in cardiovascular disease and expanding in cell and gene therapy.